If left undiagnosed and untreated for a prolonged period, fatty liver disease can progress to more serious conditions, such as cirrhosis and liver cancer.
All over the United States, countless research projects designed to improve outcomes have lost funding or been shut down. Even screening efforts targeting patients in impoverished communities have been impacted by these policies.
The first 250 patients has been enrolled in the CORCINCH-HF U.S. pivotal trial evaluating the AccuCinch Transcatheter Left Ventricular Restoration System in patients with HFrEF.
Treatment with TriClip has been consistently associated with minimal adverse events and significant improvements in quality of life. This latest update represents data from nearly 100 patients three years after implantation.
Harlan Krumholz, MD, editor-in-chief of the Journal of the American College of Cardiology (JACC), explains changes in how the journals will be reviewing articles and disseminating information.
Patients presenting for TAVR or M-TEER with baseline moderate or severe tricuspid regurgitation were associated with lower post-treatment KCCQ scores and a higher mortality rate. Perhaps treating more of these patients with tricuspid valve repair or replacement could make a difference, researchers noted.